Blocking signal transduction with related anti-PD-1 and/or anti-PD-L1 monoclonal antibodies can restore the immune response, which is a new strategy for tumor immunotherapy, but the clinical effects are quite different in different tumors 9, 10. The gene discussed is CD274; the disease is neoplasm.